


## PHCCC

<b>Cat. No.:</b>	HY-100409		
<b>CAS No.:</b>	179068-02-1		
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>14</sub> N <sub>2</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	294.3		
<b>Target:</b>	mGluR		
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



## SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 12.5 mg/mL (42.47 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM		3.3979 mL	16.9895 mL	33.9789 mL
		5 mM		0.6796 mL	3.3979 mL	6.7958 mL
		10 mM		0.3398 mL	1.6989 mL	3.3979 mL
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 1.25 mg/mL (4.25 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 1.25 mg/mL (4.25 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 1.25 mg/mL (4.25 mM); Clear solution</li> </ol>					

## BIOLOGICAL ACTIVITY

<b>Description</b>	PHCCC is a Group I mGluR antagonist with an IC <sub>50</sub> of 3 μM. PHCCC is a selective positive modulator of mGlu4 receptor. Antiparkinsonian effect <sup>[1][2]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	Group I mGluR receptors 3 μM (IC <sub>50</sub> )
<b>In Vitro</b>	PHCCC potentiated the effect of L-(+)-2-amino-4-phosphonobutyric acid (L-AP4) in inhibiting transmission at the

---

	striatopallidal synapse <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	PHCCC (75 nmol/2.5 µl; intracerebroventricular) produces an antiparkinsonian effect in a dopamine depletion akinesia model <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

[1]. Marino MJ et al. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13668-73.

[2]. Récasens M, et al. Metabotropic glutamate receptors as drug targets. Curr Drug Targets. 2007;8(5):651-681.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA